Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513696 | 0.81 | — | — | |
| SCHEMBL21645538 | 0.80 | HSD11B1 (0.40) | HSD11B1SMN1; SMN2KDM4EOPRM1OPRD1 | |
| SCHEMBL23513596 | 0.74 | HRH3 (0.40) | HSD11B1CYP2D6 | |
| SCHEMBL12524897 | 0.74 | TSHR (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL31622109 | 0.72 | FFAR4 (0.37) | HSD11B1SMN1; SMN2KDM4EOPRM1OPRD1 | |
| SCHEMBL23513771 | 0.70 | HRH3 (0.37) | ALDH1A1OPRM1 | |
| SCHEMBL1634054 | 0.70 | LMNA (0.39) | KDM4EALDH1A1CYP2D6 | |
| SCHEMBL301094 | 0.70 | — | — | |
| SCHEMBL567749 | 0.69 | FFAR3 (0.41) | HSD11B1SMN1; SMN2KDM4EALDH1A1CYP2D6 | |
| SCHEMBL567748 | 0.69 | FFAR3 (0.41) | HSD11B1SMN1; SMN2KDM4EALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | HSD11B1 1102/4885SMN1; SMN2 1987/4885KDM4E 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.